GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the user's beginner level, long-term investment preference, and the current data, Gilead Sciences Inc (GILD) is not a strong buy at the moment. While the company has strong financial performance and positive catalysts in its HIV franchise, the recent price trend is negative, and there are no significant proprietary trading signals or strong momentum indicators to suggest an immediate entry point. A hold is recommended until better technical signals or a more favorable entry price emerges.
The MACD is negatively expanding (-1.65), RSI is at 27.607 (neutral zone but nearing oversold), and moving averages are converging, indicating a lack of clear momentum. The stock is trading below key support levels (S1: 144.908, S2: 141.637), suggesting potential further downside.
Strong financial performance in Q4 2025 with revenue up 4.70% YoY, net income up 22.43% YoY, and EPS up 25.18% YoY. Positive developments in the HIV franchise with promising results from the ARTISTRY-1 trial and advancements in long-acting integrase inhibitors.
Recent price drop (-2.28% in regular market, -0.04% post-market) and lack of strong trading signals. Analysts have mixed views, with some considering the valuation 'rich' at current levels. No significant hedge fund or insider activity.
In Q4 2025, Gilead reported revenue of $7.93B (+4.70% YoY), net income of $2.18B (+22.43% YoY), EPS of $1.74 (+25.18% YoY), and gross margin of 79.57% (+0.58% YoY). These results reflect strong growth, particularly in the HIV franchise.
Analysts are generally positive, with multiple firms raising price targets (ranging from $145 to $175). However, some caution that the valuation is high at current levels. The consensus leans towards an outperform or buy rating, driven by strong HIV franchise performance and future growth potential.
